TY - JOUR
T1 - British Society of Gastroenterology guidelines on inflammatory bowel disease in adults
T2 - 2025
AU - Moran, Gordon W.
AU - Gordon, Morris
AU - Sinopolou, Vassiliki
AU - Radford, Shellie J
AU - Darie, Ana Maria
AU - Vuyyuru, Sudheer Kumar
AU - Alrubaiy, Laith
AU - Arebi, Naila
AU - Blackwell, Jonathan
AU - Butler, Thomas D
AU - Chew, Thean
AU - Colwill, Michael
AU - Cooney, Rachel
AU - De Marco, Gabriele
AU - Din, Said
AU - Din, Shahida
AU - Feakins, Roger
AU - Gasparetto, Marco
AU - Gordon, Hannah
AU - Hansen, Richard
AU - Kok, Klaartje B.
AU - Lamb, Christopher Andrew
AU - Limdi, Jimmy K.
AU - Liu, Eleanor
AU - Loughrey, Maurice B
AU - McGonagle, Dennis
AU - Patel, Kamal V.
AU - Pavlidis, Polychronis
AU - Selinger, Christian P.
AU - Shale, Matthew
AU - Smith, Philip J.
AU - Subramanian, Sreedhar
AU - Taylor, Stuart A.
AU - Zin Tun, Gloria Shwe
AU - Verma, Ajay Mark
AU - Wong, Newton A. C. S.
A2 - McLean, Mairi H
N1 - © Author(s) (or their employer(s)) 2025.
PY - 2025/6/23
Y1 - 2025/6/23
N2 - In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revised in 2019. These updated guidelines aim to complement the IBD standards and promote the use of the national primary care diagnostic pathway for lower gastrointestinal symptoms to enhance diagnostic accuracy and timeliness. Formulated through a systematic and transparent process, this document reflects a consensus of best practices based on current evidence. The guideline, while developed primarily for the UK, is structured to support IBD management internationally. It is endorsed by the BSG executive board and CSSC without external commercial funding, with involvement primarily supported through professional roles in public institutions and the National Health Service (NHS). Methodological revisions since the prior guidelines have enhanced rigor in technical review and development, with methodology details published independently following peer review. In developing the recommendations, 89 clinical experts and stakeholders participated in an online survey, identifying primary outcomes, such as clinical and endoscopic remission, as well as adverse event metrics, all stratified by clinically relevant effect sizes. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges.
AB - In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revised in 2019. These updated guidelines aim to complement the IBD standards and promote the use of the national primary care diagnostic pathway for lower gastrointestinal symptoms to enhance diagnostic accuracy and timeliness. Formulated through a systematic and transparent process, this document reflects a consensus of best practices based on current evidence. The guideline, while developed primarily for the UK, is structured to support IBD management internationally. It is endorsed by the BSG executive board and CSSC without external commercial funding, with involvement primarily supported through professional roles in public institutions and the National Health Service (NHS). Methodological revisions since the prior guidelines have enhanced rigor in technical review and development, with methodology details published independently following peer review. In developing the recommendations, 89 clinical experts and stakeholders participated in an online survey, identifying primary outcomes, such as clinical and endoscopic remission, as well as adverse event metrics, all stratified by clinically relevant effect sizes. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges.
U2 - 10.1136/gutjnl-2024-334395
DO - 10.1136/gutjnl-2024-334395
M3 - Article
C2 - 40550582
SN - 0017-5749
VL - 74
SP - s1-s101
JO - Gut
JF - Gut
ER -